Koers Vivoryon Therapeutics AG Euronext Amsterdam
Aandelen
DE0007921835
Biotechnologie & Medisch Onderzoek
Omzet 2023 | -3,62K -3,87K | Omzet 2024 * | - | Marktkapitalisatie | 20,85 mln. 22,3 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -28 mln. -29,94 mln. | Nettowinst (verlies) 2024 * | -18 mln. -19,25 mln. | EV/omzet 2023 | -53.497 x |
Nettoliquiditeiten 2023 | 18,52 mln. 19,81 mln. | Nettoliquiditeiten 2024 * | 19,55 mln. 20,9 mln. | EV/omzet 2024 * | - |
K/w-verhouding 2023 |
-7,27
x | K/w-verhouding 2024 * |
-1,12
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 66,56% |
Recentste transcriptie over Vivoryon Therapeutics AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 01-01-12 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 31-08-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 74 | 01-01-07 | |
Director/Board Member | 54 | 01-01-07 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |